MaaT Pharma S.A. (MAAT.PA)
MaaT Pharma S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Lyon, ARA, FR. The stock last traded at $2.90, up 1.40% on the session, giving a market capitalisation of $54.6M. Its beta of 0.40 implies it has historically moved less than the broad market.
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
MaaT Pharma S.A. is most often compared with the following Healthcare names: